The Pep Edit Newsletter

Cheat sheet

Status: Not FDA-approved Reviewed

MOTS-c

A mitochondrial-encoded peptide. The interesting claim is pathway overlap with exercise, not a replacement for it.

The evidence rail

How to read this
  1. Mechanistic: reached
  2. Cell research: reached
  3. Animal research: reached
  4. Human observational: reached, limited data
  5. Human clinical trial: not reached
  6. Established clinical use: not reached
Evidence
Early human dataRung 4 of 6, limited data. People were observed, surveyed, or followed, or given the peptide in a small study with no comparison group. Useful for patterns, silent on cause.
Status
Not FDA-approvedNot approved for use as a drug. Often sold as a research chemical.

Why people are talking about it

It is often described online as exercise in a vial, and longevity communities are drawn to anything made by the mitochondria.

What has it been studied for?

  • Metabolic signaling, including AMPK-related pathways
  • Exercise-adjacent biology in early work

What we know

  • The analogy to exercise is specific enough to be useful, and easy to overclaim

What we don’t

  • Whether that analogy survives larger human studies

What is known about safety

  • The FDA says it has not identified any human exposure data for drug products containing MOTS-c, by any route, and does not know whether it would cause harm in people
  • The human data that does exist mostly measures the MOTS-c your own body makes, for example after exercise. That is not the same as taking it
  • A related drug candidate built on MOTS-c has completed an early safety study, but it is a different molecule
  • Products sold online as research chemicals are not checked for identity, purity, or sterility

Bottom line

Shares a pathway with exercise. Does not replace it.

Education only. Not medical advice. Not a protocol.

Sources

  1. Cells and miceThe mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (opens in a new tab)Lee and colleagues, Cell Metabolism, 2015
  2. Mice, plus measurements of natural MOTS-c in exercising peopleMOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (opens in a new tab)Reynolds and colleagues, Nature Communications, 2021
  3. Early human trial of a related moleculeA phase 1a/1b study of CB4211 in healthy non-obese subjects and subjects with nonalcoholic fatty liver disease (NCT03998514) (opens in a new tab)ClinicalTrials.gov registry entry for a MOTS-c analog, status completed
  4. Regulator statementCertain bulk drug substances for use in compounding that may present significant safety risks (opens in a new tab)US Food and Drug Administration, current as of April 2026

We link to the paper, the trial registry, or the regulator, never to a seller. A study type in the label tells you who or what was actually studied.

Spotted an error or a newer study? Tell the editors. Corrections are noted on the page. Our standards.

Keep reading

  • BPC-157

    Widely discussed for gut and recovery. The animal literature is large. Human clinical evidence is still thin.

    Evidence: Limited human data. Reached rung 4 of 6, Human observational, with limited data.Not FDA-approved
    Gut healthRecoveryInflammation
    Gut / Recovery

  • KPV

    A fragment of alpha-MSH studied for inflammation and skin. Research so far is in cells and animals.

    Evidence: Animal research. Reached rung 3 of 6, Animal research.Not FDA-approved
    InflammationGut healthSkin + hair
    Inflammation

  • Larazotide

    One of the few names in this space with multiple human trials, studied around celiac and tight junctions.

    Evidence: Human clinical trials. Reached rung 5 of 6, Human clinical trial.Investigational
    Gut health
    Gut

Every new sheet, once a month.

One email a month. The study type named, every time.